Chronic hepatitis B remains a major global health challenge due to morbidity and mortality
from hepatocellular carcinoma and complications of liver cirrhosis. Current treatment
regimens are non-curative and, once initiated, treatment is of indefinite duration for the
majority. The decision to initiate treatment decisions is based on risk stratification. Advances
in our understanding of the natural history of chronic hepatitis B have led to a paradigm shift
in recommendations for treatment. Emerging non-invasive biomarkers of disease activity will …